NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...
October 2024, saw significant FDA actions and clinical trial updates that shaped cancer treatment progress. Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback